Nalmefene Autoinjector (Zurnai) for Reversal of Opioid Overdose
Abstract
Zurnai (Purdue), an autoinjector formulation of the opioid antagonist nalmefene, has been approved by the FDA for intramuscular (IM) or subcutaneous (SC) emergency treatment of known or suspected opioid overdose in persons ≥12 years old.1 Naloxone, another opioid antagonist, has been available in single-use syringes for years. Both nalmefene and naloxone are also available in nasal sprays; some naloxone nasal sprays (Narcan, and others) are available over the counter.
Fields of Study & Subjects
Opioid Use Disorder Treatment
Veterinary Pharmacology and Anesthesia
Poisoning and overdose treatments
Publication details
- Journal / source
- The medical letter on drugs and therapeutics/The medical letter
- Publisher
- The Medical Letter, Inc.
- Volume
- 68
- Issue
- 1746
- Pages
- 10–12
- Publication date
- 19 January 2026
- Language
- EN